Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Shattuck Labs (NASDAQ: STTK) granted inducement equity awards on Dec 10, 2025 to a newly hired non-executive officer under Nasdaq Listing Rule 5635(c)(4).

The awards are non-qualified stock options to purchase 206,000 shares at an exercise price of $3.23 per share, with a maximum term of 10 years. Vesting is 25% on Nov 17, 2026 and the remainder vests in equal monthly installments over the following 36 months. The awards were granted outside the Company’s 2020 Equity Incentive Plan but are generally subject to the same terms and were approved by the independent Compensation Committee.

Key Figures

Inducement options 206,000 shares Non-qualified stock options granted to a newly hired non-executive officer

Exercise price $3.23 per share Strike price for inducement stock options

Option term 10 years Maximum term of inducement stock options

Initial vesting tranche 25% Portion of award vesting on November 17, 2026

Remaining vesting period 36 months Remaining options vest monthly after November 17, 2026

Grant Date December 10, 2025 Date inducement equity awards were granted

Current price $3.10 Pre-news trading price on analysis date

52-week range $0.6922 – $3.38 52-week low and high before this news

Market Reality Check

$3.06 Last Close

Volume Volume 159,593 is about 51% below the 20-day average of 328,336 (muted trading pre-news). low

Technical Shares at $3.10 are trading above the 200-day MA of $1.39 and 8.28% below the $3.38 52-week high.

Peers on Argus

STTK was down 4.02% while peers showed mixed moves: IFRX +1.94%, ANIX -28.4%, ATRA +0.98%, MGNX -2.78%, SRZN +3.67%. This points to a stock-specific move rather than a sector-wide trend.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 20	Investor conferences	Neutral	-1.5%	Announced participation in multiple December 2025 investor conferences.
Nov 06	Earnings and pipeline	Positive	+1.0%	Reported Q3 2025 results and SL-325 progress with funding into 2029.
Oct 02	KOL panel	Neutral	-0.4%	Disclosed participation in a Wedbush KOL and company panel post-UEGW.
Aug 26	Private placement, board	Positive	+2.6%	Closed up to $103M private placement and refreshed Board of Directors.
Aug 21	IND effective	Positive	-11.4%	IND for SL-325 became effective for IBD with Phase 1 trial plans.

Pattern Detected

Recent news has produced mixed reactions: financing and earnings updates often saw modest gains, while an IND effectiveness update coincided with a double‑digit decline, indicating occasional negative divergence on seemingly positive clinical milestones.

Recent Company History

Over the last several months, Shattuck reported multiple strategic and clinical milestones. In August 2025, it secured a private placement of up to $103 million and announced its IND for SL-325 was in effect, enabling a Phase 1 trial targeting IBD. Subsequent participation in KOL and investor conferences through October–December 2025 highlighted growing visibility. Q3 2025 results on Nov 6, 2025 showed a narrowed net loss of $10.1M and cash and investments of about $86.1M. Today’s inducement option grant fits within this ongoing build‑out of talent and governance.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-09-18

The company has an active Form S-3 shelf registration dated 2025-09-18, allowing it to offer common stock and warrant securities in the future. The filing includes detailed beneficial ownership tables and a securities purchase agreement but does not specify a total shelf dollar amount in the provided summary.

Market Pulse Summary

This announcement details a standard inducement equity grant of 206,000 non-qualified stock options at an $3.23 exercise price, vesting over roughly four years under Nasdaq Listing Rule 5635(c)(4). It adds to Shattuck’s broader use of equity incentives alongside prior private placement financing and an active S-3 shelf. Investors may watch total potential share overhang, future equity-based compensation, and progress on SL-325 and other programs as key ongoing considerations.

Key Terms

non-qualified stock options financial

"The inducement awards consist of non-qualified stock options to purchase 206,000 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

exercise price financial

"common stock with an exercise price of $3.23 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"25% of the award will vest on November 17, 2026, with the remainder vesting in equal monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Nasdaq Listing Rule 5635(c)(4) regulatory

"approved by Shattuck’s independent Compensation Committee, in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

Equity Incentive Plan financial

"granted outside of the Company’s 2020 Equity Incentive Plan, but are generally subject to the same terms"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

AI-generated analysis. Not financial advice.

AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on December 10, 2025 (the “Grant Date”) to a newly-hired non-executive officer.

The inducement awards consist of non-qualified stock options to purchase 206,000 shares of Shattuck’s common stock with an exercise price of $3.23 per share. The stock options have a maximum term of 10 years. A total of 25% of the award will vest on November 17, 2026, with the remainder vesting in equal monthly installments over the subsequent 36 months. The stock options were granted as a material inducement to the individual’s employment and were approved by Shattuck’s independent Compensation Committee, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted outside of the Company’s 2020 Equity Incentive Plan, but are generally subject to the same terms and conditions that apply to awards granted under such plan.

About Shattuck Labs, Inc.

Shattuck Labs, Inc. is a clinical-stage biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor & Media Contact:

Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

FAQ

What inducement awards did Shattuck Labs (STTK) grant on Dec 10, 2025?

Shattuck granted non-qualified stock options to purchase 206,000 shares at an exercise price of $3.23 per share.

When do the Shattuck Labs (STTK) inducement options begin vesting and what is the schedule?

The options vest 25% on Nov 17, 2026, with the remainder vesting in equal monthly installments over the next 36 months.

What is the term length for the stock options granted by Shattuck Labs (STTK)?

The stock options have a maximum term of 10 years from the grant date.

Were Shattuck Labs (STTK) inducement awards granted under the company’s 2020 Equity Incentive Plan?

No; the awards were granted outside the 2020 Equity Incentive Plan but are generally subject to the same terms and conditions.

Why did Shattuck Labs (STTK) issue the inducement awards under Nasdaq Listing Rule 5635(c)(4)?

The awards were granted as a material inducement to the individual’s employment and approved under Nasdaq Listing Rule 5635(c)(4).

How might the Dec 10, 2025 inducement grant affect existing Shattuck Labs (STTK) shareholders?

The filing discloses the option size, exercise price, term, and vesting schedule but does not quantify dilution or share-count impact.